Analysis of Iliac Crest Biopsies From Patients Receiving Risedronate
- First Posted Date
- 2009-02-05
- Last Posted Date
- 2013-06-05
- Lead Sponsor
- Warner Chilcott
- Target Recruit Count
- 29
- Registration Number
- NCT00837746
- Locations
- 🇺🇸
Ronald D Emkey, MD, Wyomissing, Pennsylvania, United States
🇺🇸Maria Greenwald, MD, Palm Desert, California, United States
🇺🇸Paul Miller, MD, Lakewood, Colorado, United States
Bioequivalence of Testosterone Reduced-size Patch Relative to the Testosterone Reference Patch
- First Posted Date
- 2008-11-17
- Last Posted Date
- 2013-04-17
- Lead Sponsor
- Warner Chilcott
- Target Recruit Count
- 110
- Registration Number
- NCT00791856
- Locations
- 🇺🇸
Antonio Pizarro, MD, Fort Myers, Florida, United States
🇺🇸David R Mathews, MD, Overland Park, Kansas, United States
🇺🇸Maria J Gulierrez, MD, Miramar, Florida, United States
Fecal Biomarker Study for Patients With Ulcerative Colitis
- Conditions
- Ulcerative Colitis
- First Posted Date
- 2008-10-27
- Last Posted Date
- 2013-05-31
- Lead Sponsor
- Warner Chilcott
- Target Recruit Count
- 89
- Registration Number
- NCT00780507
- Locations
- 🇺🇸
Research Facility, Spokane, Washington, United States
Study of Bone Histomorphometry, Microarchitecture, and Matrix Structure in Patients Receiving Alendronate or Risedronate
- Conditions
- Postmenopausal Osteoporosis
- First Posted Date
- 2008-10-23
- Last Posted Date
- 2013-06-05
- Lead Sponsor
- Warner Chilcott
- Target Recruit Count
- 105
- Registration Number
- NCT00778154
- Locations
- 🇨🇦
Warner Chilcott Research Facility, Montreal, Quebec, Canada
Assess the Influence of a High-fat Meal on the Relative Bioavailability Of Two Formulations of Risedronate
- First Posted Date
- 2008-09-19
- Last Posted Date
- 2011-10-12
- Lead Sponsor
- Warner Chilcott
- Target Recruit Count
- 76
- Registration Number
- NCT00755872
- Locations
- 🇺🇸
Research Site, Austin, Texas, United States
Pharmacokinetics of Asacol 2.4 g/Day and Lialda 2.4 g/Day in Healthy Volunteers
- First Posted Date
- 2008-09-12
- Last Posted Date
- 2013-04-17
- Lead Sponsor
- Warner Chilcott
- Target Recruit Count
- 37
- Registration Number
- NCT00751699
- Locations
- 🇺🇸
Research Site, Miami, Florida, United States
Food Effects on the Relative Bioavailability of Different Dosages of Risedronate
- Conditions
- PostmenopausalNon-lactatingSurgically Sterile
- Interventions
- First Posted Date
- 2008-07-16
- Last Posted Date
- 2011-10-12
- Lead Sponsor
- Warner Chilcott
- Target Recruit Count
- 94
- Registration Number
- NCT00717145
- Locations
- 🇺🇸
Research Site, Austin, Texas, United States
🇺🇸Research site, Miramar, Florida, United States
Assessing the Safety/Efficacy of Asacol® Given Every 12 Hours to Children and Adolescents With Active Ulcerative Colitis
- First Posted Date
- 2008-07-11
- Last Posted Date
- 2012-04-05
- Lead Sponsor
- Warner Chilcott
- Target Recruit Count
- 83
- Registration Number
- NCT00713310
- Locations
- 🇷🇴
Research Site, Iasi, Romania
🇨🇦Research Facility, Montreal, Quebec, Canada
A Two-week Open-label Pharmacodynamic and Pharmacokinetic Study of Multiple Doses of a Darifenacin Liquid Oral Suspension in Children (2 - 15 Years) With Neurogenic Detrusor Overactivity
- First Posted Date
- 2008-07-09
- Last Posted Date
- 2022-06-09
- Lead Sponsor
- Warner Chilcott
- Target Recruit Count
- 35
- Registration Number
- NCT00712322
- Locations
- 🇺🇸
Children's Hospital of Michigan, Detroit, Michigan, United States
🇺🇸Pediatric Urology Associates, PC, Lake Success, New York, United States
🇺🇸Washington University Pediatric Urology, Saint Louis, Missouri, United States
Assess Bioequivalence of One 150 mg Risedronate Tablet Versus Two 75 mg Risedronate Tablets in Healthy Subjects
- First Posted Date
- 2008-06-18
- Last Posted Date
- 2013-04-17
- Lead Sponsor
- Warner Chilcott
- Target Recruit Count
- 96
- Registration Number
- NCT00699777
- Locations
- 🇺🇸
Research Site, Gainesville, Florida, United States
🇺🇸Research Facility, Dallas, Texas, United States